United States //   News Releases

News Releases

News Releases

Date Title and Summary Additional Formats
Toggle Summary Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)--Dec. 13, 2018-- Endologix, Inc.  (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to three newly hired employees (together, the “Awardees”).
View HTML
Toggle Summary Endologix Honors Innovators of Aortic Therapy at VEITHsymposium
IRVINE, Calif. --(BUSINESS WIRE)--Nov. 15, 2018-- Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today honored four innovators of aortic therapy at the 45 th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons
View HTML
Toggle Summary Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)--Nov. 8, 2018-- Endologix, Inc.  (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today the grant of inducement equity awards to three newly hired employees (together, the “Awardees”).
View HTML
Toggle Summary Endologix Reports Third Quarter 2018 Financial Results
IRVINE, Calif. --(BUSINESS WIRE)--Nov. 1, 2018-- Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the third quarter ended September 30, 2018 . “While there is still significant work to be
View HTML
Toggle Summary Endologix, Inc. to Present at Two Investor Conferences in November
IRVINE, Calif. --(BUSINESS WIRE)--Oct. 29, 2018-- Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will present at the following two investor conferences in November: Conference: Stephens NY Investment Conference
View HTML
Toggle Summary Endologix Announces Pricing of Public Offering of Common Stock
IRVINE, Calif. --(BUSINESS WIRE)--Oct. 25, 2018-- Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), developer and marketer of innovative treatments for aortic disorders, announced today the pricing of a registered underwritten public offering of its common stock for net proceeds of
View HTML
Toggle Summary Endologix Announces Public Offering of Common Stock
IRVINE, Calif. --(BUSINESS WIRE)--Oct. 24, 2018-- Endologix, Inc. (Nasdaq:ELGX) (“Endologix” or the “Company”), developer and marketer of innovative treatments for aortic disorders, announced today that it has commenced a registered underwritten public offering of  $20.0 million  of its shares of
View HTML
Toggle Summary Endologix, Inc. to Announce Third Quarter 2018 Financial Results on November 1, 2018
IRVINE, Calif. --(BUSINESS WIRE)--Oct. 22, 2018-- Endologix, Inc.  (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the third quarter of fiscal year 2018 after the market close on Thursday, November 1,
View HTML
Toggle Summary FDA Classifies Previous Endologix AFX Safety Notice as Class I Recall
IRVINE, Calif. --(BUSINESS WIRE)--Oct. 5, 2018-- Endologix® Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has received notice that the U.S. Food and Drug Administration ( FDA ) has classified a voluntary recall action that
View HTML
Toggle Summary Endologix Announces Third Quarter Preliminary Revenue Results and Raises Low End of 2018 Revenue Guidance Range
The Company provides teleconference and webcast details for Investor Meeting IRVINE, Calif. --(BUSINESS WIRE)--Oct. 2, 2018-- Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the third
View HTML
Toggle Summary Endologix Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
IRVINE, Calif. --(BUSINESS WIRE)--Aug. 23, 2018-- Endologix , Inc. (Nasdaq: ELGX) (the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced the grant of inducement equity awards to three newly appointed executives (together, the “Awardees”).
View HTML
Toggle Summary Endologix to Host Investor Meeting on October 2, 2018
IRVINE, Calif. --(BUSINESS WIRE)--Aug. 23, 2018-- Endologix, Inc. (Nasdaq:ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it will host a meeting for financial analysts and investment professionals at 4:15 p.m.
View HTML
Toggle Summary Endologix Appoints Jeffrey S. Brown as Chief Operations Officer
IRVINE, Calif. --(BUSINESS WIRE)--Aug. 15, 2018-- Endologix, Inc. (Nasdaq:ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed Jeffrey S. Brown as the Company’s Chief Operations Officer, effective as of
View HTML
Toggle Summary Endologix Reports Second Quarter 2018 Financial Results
IRVINE, Calif. --(BUSINESS WIRE)--Aug. 9, 2018-- Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2018. The Company reported global revenue of $44.7 million in the second
View HTML
Toggle Summary Endologix, Inc. to Announce Second Quarter 2018 Financial Results on August 9, 2018
IRVINE, Calif. --(BUSINESS WIRE)--Jul. 16, 2018-- Endologix , Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the second quarter of fiscal year 2018 after the market close on Thursday, August 9,
View HTML